Author's response to reviews

Title: Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: the experience of the Hellenic Cooperative Oncology Group.

Authors:

Aristotle Bamias (abamias@med.uoa.gr)
Christos Papadimitriou (abamias@med.uoa.gr)
Eleni Efstadthiou (abamias@med.uoa.gr)
Alexandros Rodolakis (abamias@med.uoa.gr)
Georgios Vlahos (abamias@med.uoa.gr)
Zannis Voulgaris (abamias@med.uoa.gr)
Georgios Bozas (gbozas@med.uoa.gr)
Georgios Fountzilas (fountzil@med.auth.gr)
Gerassimos Aravantinos (hecogaga@otenet.gr)
Evagelia Razis (edrazis@hol.gr)
Dimitra Gika (mdimop@med.uoa.gr)
Meletios A. Dimopoulos (mdimop@med.uoa.gr)

Version: 4 Date: 19 September 2006

Author's response to reviews:

Alexander Pemberton, PhD

BMC Cancer Athens 16 September 2006

Re: MS 1103156207983361

FOUR CYCLES OF PACLITAXEL AND CARBOPLATIN AS ADJUVANT TREATMENT IN EARLY-STAGE OVARIAN CANCER: A SIX-YEAR EXPERIENCE OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP.


Dear Sir,

Thank you for your recent reply after the resubmission of our manuscript. We have now addressed your points according to the list below and we hope that in the present form our manuscript will be acceptable for publication in BMC Cancer.

1. The abstract, the text, the references and the tables have been formatted according to the "BMC medicine journals-Author's checklist for manuscript formatting" and the respective template.

2. The figures have been cropped and the A and B parts have been submitted in single figure files.

3. Regarding the Ethics, it is clearly stated in the title, last paragraph of the Background and the Methods sections and has already been discussed in reply to Reviewers' comments, that this was not a prospective study but a retrospective analysis of our experience on a treatment, which was then and still is widely used to treat early-stage ovarian cancer outside the context of prospective clinical trials. Therefore, no IRB approval or informed consent were obtained, since this was "standard" treatment and no prospective study. The analysis was approved by the Scientific Committee of the Hellenic Cooperative Oncology Group and
this is now stated in the Methods.

4. We accept the processing charges, which will be paid by the Hellenic Cooperative Oncology Group. The invoice should be sent to HELLENIC COOPERATIVE ONCOLOGY GROUP, 18 Hantzikonstanti st, Ampelokipi, Athens 115 24 or faxed to 0030 210 6912713.

Thank you for giving us the opportunity to resubmit our manuscript.

Yours sincerely

Aristotle Bamias, PhD, MRCP (UK)